Therapeutic effectiveness of intratympanic and retroauricular methylprednisolone sodium succinate for refractory sudden sensorineural hearing loss in diabetic patients

Figure 1 The flowchart illustrating the design of this research. MPSS: Methylprednisolone sodium succinate; RSSHL: Refractory sudden sensorineural hearing loss; DM: Diabetes mellitus.

Figure 2 Blood glucose of two groups. A: Changes in fasting blood glucose before and after treatment; B: Changes in 2-hour postprandial blood glucose before and after treatment; C: Pre- and post-treatment glycosylated hemoglobin in two groups. ^aP < 0.05, ^bP < 0.01 in the inter-group comparison. FBG: Fasting blood glucose; 2hPBG: 2-hour postprandial blood glucose; HbA1c: Glycosylated hemoglobin.

Figure 3 Hearing thresholds at different frequencies in two groups. A: The hearing threshold at 250 Hz in both groups; B: The hearing threshold at 500 Hz in both groups; C: The hearing threshold at 1000 Hz in both groups. ^aP < 0.05, ^bP < 0.01 in the inter-group comparison.

Figure 4 Serum biochemical indexes of the two groups. A: Changes in interleukin-6 in the two groups before and after treatment; B: Changes in C-reactive protein before and after treatment in the two groups; C: Pre- and post-treatment procalcitonin in two groups. ^aP < 0.05, ^bP < 0.01 in the inter-group comparison. IL-6: Interleukin-6; CRP: C-reactive protein; PCT: Post-treatment procalcitonin.

Figure 5 Quality of life of the two groups. A: Changes in energy before and after treatment; B: Changes in social functioning before and after treatment; C: Changes in role functioning before and after treatment; D: Changes in body functioning before and after treatment; E: Changes in mental health before and after treatment; F: Changes in overall health changes before and after treatment. ^aP < 0.05, ^bP < 0.01 in the inter-group comparison.